

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2016233485 B2**

(54) Title
Fixed dose combinations and formulations comprising ETC1002 and Ezetimibe and methods of treating or reducing the risk of cardiovascular disease

(51) International Patent Classification(s)
A61K 31/194 (2006.01) **A61K 31/397** (2006.01)

(21) Application No: **2016233485** (22) Date of Filing: **2016.03.14**

(87) WIPO No: **WO16/149191**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/250,921	2015.11.04	US
62/133,128	2015.03.13	US

(43) Publication Date: **2016.09.22**

(44) Accepted Journal Date: **2021.05.20**

(71) Applicant(s)
Esperion Therapeutics, Inc.

(72) Inventor(s)
Newton, Roger Schofield;Rosenberg, Noah Laban;MacDougall, Diane Elaine

(74) Agent / Attorney
FB Rice Pty Ltd, Level 23 44 Market Street, Sydney, NSW, 2000, AU

(56) Related Art
ESPERION THERAPEUTICS "Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia" Esperion Press Release 1 October 2014
GAGNE, C. et al. "Efficacy and Safety of Ezetimibe Monotherapy in 6-10 Year Old Children with Heterozygous Familial or Non-familial Hypercholesterolemia" J. Clin. Lipidol. (2013) vol. 7, pages 257-258
US 2005/0043278 A1
MASUDA, D. et al. "Ezetimibe improves postprandial hyperlipidemia in patients with type IIb hyperlipidemia" European Journal of Clinical investigation (2009) vol. 39, pages 689-698
NIKOLIC, D. et al. "ETC-1002: A future option for lipid disorders?" Atherosclerosis (2014) vol. 237, pages 705-710